146 related articles for article (PubMed ID: 24377585)
1. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma.
Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585
[TBL] [Abstract][Full Text] [Related]
2. Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy.
Wei GL; Huang XE; Huo JG; Wang XN; Tang JH
Asian Pac J Cancer Prev; 2013; 14(5):2703-6. PubMed ID: 23803018
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
5. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
Hainsworth JD; Cebotaru CL; Kanarev V; Ciuleanu TE; Damyanov D; Stella P; Ganchev H; Pover G; Morris C; Tzekova V
J Thorac Oncol; 2010 Oct; 5(10):1630-6. PubMed ID: 20802351
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).
Hattori Y; Iwasaku M; Satouchi M; Nishiyama A; Korogi Y; Otsuka K; Fujita S; Katakami N; Mori M; Nishino K; Morita S; Negoro S
Jpn J Clin Oncol; 2013 Dec; 43(12):1184-9. PubMed ID: 24168805
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study.
Zhang DS; Jin Y; Luo HY; Wang ZQ; Qiu MZ; Wang FH; Li YH; Xu RH
Br J Cancer; 2015 Jan; 112(2):266-70. PubMed ID: 25474247
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Wu XY; Huang XE; You SX; Lu YY; Cao J; Liu J
Asian Pac J Cancer Prev; 2013; 14(3):2019-22. PubMed ID: 23679311
[TBL] [Abstract][Full Text] [Related]
9. Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers.
Qian T; Huang XE
Asian Pac J Cancer Prev; 2015; 16(11):4791-5. PubMed ID: 26107242
[TBL] [Abstract][Full Text] [Related]
10. Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs.
Lu YY; Huang XE; Xu L; Liu DG; Cao J; Wu XY; Liu J; Xiang J
Asian Pac J Cancer Prev; 2013; 14(3):2005-8. PubMed ID: 23679308
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.
Jalal S; Ansari R; Govindan R; Bhatia S; Bruetman D; Fisher W; Masters G; White A; Stover D; Yu M; Hanna N;
J Thorac Oncol; 2009 Jan; 4(1):93-6. PubMed ID: 19096313
[TBL] [Abstract][Full Text] [Related]
12. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
[TBL] [Abstract][Full Text] [Related]
13. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma.
Lau DH; Moon J; Davies AM; Sanborn RE; Hirsch FR; Franklin WA; Ruzich JC; Redman MW; Gandara DR
Clin Lung Cancer; 2013 Jul; 14(4):351-5. PubMed ID: 23415808
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
[TBL] [Abstract][Full Text] [Related]
16. Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study.
Chang GC; Tsai CM; Hsia TC; Yang CH; Abdulnabi R; Blair JM; Linn C
J Formos Med Assoc; 2013 Sep; 112(9):518-26. PubMed ID: 24060197
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Russo F; Bearz A; Pampaloni G;
BMC Cancer; 2008 Jul; 8():216. PubMed ID: 18667090
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Zhang RX; Cai DY; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):869-72. PubMed ID: 23291140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
